TrialsgrambetaRCTs are beautiful

FUEL

2020

Fontan Udenafil Exercise Longitudinal Trial

In 400 adolescents with Fontan circulation, udenafil did not significantly improve peak oxygen consumption compared with placebo, although exercise performance at the ventilatory anaerobic threshold improved.

Result

Change in peak oxygen consumption at 26 weeks
Absolute difference
3.0 points

The absolute difference is derived from the event rates.

Also reported: Primary endpoint missed. At the ventilatory anaerobic threshold, VO₂ (p=0.012), ventilatory efficiency (p=0.014) and work rate (p=0.021) all improved.

Original publication
Subtopic
Fontan circulation
Design
Phase-3, double-blind, placebo-controlled RCT over 26 weeks
Relevance
Supporting: context rather than must-know.
Source
Goldberg DJ, Zak V, Goldstein BH, et al. Circulation. 2020;141(8):641-651.doi 10.1161/CIRCULATIONAHA.119.044352

Discussion & critique

The primary endpoint was formally missed and the submaximal gains are of uncertain clinical relevance, in a young and unusually well cohort. It is by far the largest randomised pharmacotherapy trial ever conducted in Fontan physiology and is why PDE5 inhibition remains an option rather than standard care.